Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymol-loaded niosome gel 1% for recurrent vulvovaginal candidiasis
IRCT20210611051539N5Phase 3Recruiting
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of thymol in recurrent vulvovaginal candidiasis (RVVC), sponsored by Mazandaran University of Medical Sciences. Started Jul 2026; status: recruiting.
02
Drugs
thymol
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on IRCT20210611051539N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210611051539N5.